Arrowstreet Capital
TGTX icon

Arrowstreet Capital’s TG Therapeutics TGTX Stock Holding History

Arrowstreet Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-171,496
Closed -$2.93M – 1769
2023
Q4 		$2.93M Buy
+171,496
New +$1.99M ﹤0.01% 880
2019
Q2 		– Sell
-78,009
Closed -$627K – 1692
2019
Q1 		$627K Buy
+78,009
New +$422K ﹤0.01% 1431

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Arrowstreet Capital's TGTX Position: Q1 2024 in Review

Arrowstreet Capital sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 171,496 shares — an estimated $2.93M sold.

Arrowstreet Capital first reported a position in TGTX in Q1 2019 and held it in 2 quarters. The position peaked at $2.93M in Q4 2023. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • Arrowstreet Capital reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Arrowstreet Capital sold 171,496 TG Therapeutics shares in Q1 2024, an estimated $2.93M.
  • Arrowstreet Capital first reported a position in TG Therapeutics in Q1 2019 and held it in 2 quarters.
  • Arrowstreet Capital's TG Therapeutics position peaked at $2.93M in Q4 2023.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Arrowstreet Capital's 13F filing for Q1 2024, filed 15 May 2024.